Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease

Karl Migally, Elizabeth A Braunlin, Lei Zhang, Bryce A Binstadt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BackgroundHigh-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD). Practice regarding HDA varies, and it is unclear whether HDA duration affects the long-term course.MethodsWe retrospectively studied KD patients at our hospital for over 10 years. Patients were categorized as having received HDA for 0, 1-7, or >7 days. Primary outcome was the maximum coronary Z-score at diagnosis and follow-up; secondary outcomes included inflammatory markers.ResultsOne hundred and three patients had HDA duration documented, of which 35 patients had coronary artery abnormalities (CAAs) at diagnosis. There was no difference in demographics or inflammatory markers between the HDA groups, and no difference in HDA duration between patients with or without CAAs. Seventeen patients received no HDA; they had longer illness and defervescence duration before diagnosis, and were less likely to receive IVIg. For CAAs, multivariate regression revealed that HDA duration did not predict the coronary Z-score at 9-15 months. Higher Z-score at diagnosis was associated with higher Z-score at 9-15 months.ConclusionThe only factor associated with coronary Z-score at 9-15 months was the Z-score at diagnosis. At our institution, longer illness and defervescence duration and the lack of IVIg administration were associated with not administering HDA. HDA duration did not affect the clinically relevant outcomes, particularly CAA persistence.

Original languageEnglish (US)
Pages (from-to)1136-1145
Number of pages10
JournalPediatric Research
Volume83
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Mucocutaneous Lymph Node Syndrome
Aspirin
Coronary Vessels
Intravenous Immunoglobulins
Therapeutics
Intravenous Administration
Demography

Cite this

Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease. / Migally, Karl; Braunlin, Elizabeth A; Zhang, Lei; Binstadt, Bryce A.

In: Pediatric Research, Vol. 83, No. 6, 01.06.2018, p. 1136-1145.

Research output: Contribution to journalArticle

@article{52133ab4eab8443ab249de8fca4e4ca6,
title = "Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease",
abstract = "BackgroundHigh-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD). Practice regarding HDA varies, and it is unclear whether HDA duration affects the long-term course.MethodsWe retrospectively studied KD patients at our hospital for over 10 years. Patients were categorized as having received HDA for 0, 1-7, or >7 days. Primary outcome was the maximum coronary Z-score at diagnosis and follow-up; secondary outcomes included inflammatory markers.ResultsOne hundred and three patients had HDA duration documented, of which 35 patients had coronary artery abnormalities (CAAs) at diagnosis. There was no difference in demographics or inflammatory markers between the HDA groups, and no difference in HDA duration between patients with or without CAAs. Seventeen patients received no HDA; they had longer illness and defervescence duration before diagnosis, and were less likely to receive IVIg. For CAAs, multivariate regression revealed that HDA duration did not predict the coronary Z-score at 9-15 months. Higher Z-score at diagnosis was associated with higher Z-score at 9-15 months.ConclusionThe only factor associated with coronary Z-score at 9-15 months was the Z-score at diagnosis. At our institution, longer illness and defervescence duration and the lack of IVIg administration were associated with not administering HDA. HDA duration did not affect the clinically relevant outcomes, particularly CAA persistence.",
author = "Karl Migally and Braunlin, {Elizabeth A} and Lei Zhang and Binstadt, {Bryce A}",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/pr.2018.44",
language = "English (US)",
volume = "83",
pages = "1136--1145",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease

AU - Migally, Karl

AU - Braunlin, Elizabeth A

AU - Zhang, Lei

AU - Binstadt, Bryce A

PY - 2018/6/1

Y1 - 2018/6/1

N2 - BackgroundHigh-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD). Practice regarding HDA varies, and it is unclear whether HDA duration affects the long-term course.MethodsWe retrospectively studied KD patients at our hospital for over 10 years. Patients were categorized as having received HDA for 0, 1-7, or >7 days. Primary outcome was the maximum coronary Z-score at diagnosis and follow-up; secondary outcomes included inflammatory markers.ResultsOne hundred and three patients had HDA duration documented, of which 35 patients had coronary artery abnormalities (CAAs) at diagnosis. There was no difference in demographics or inflammatory markers between the HDA groups, and no difference in HDA duration between patients with or without CAAs. Seventeen patients received no HDA; they had longer illness and defervescence duration before diagnosis, and were less likely to receive IVIg. For CAAs, multivariate regression revealed that HDA duration did not predict the coronary Z-score at 9-15 months. Higher Z-score at diagnosis was associated with higher Z-score at 9-15 months.ConclusionThe only factor associated with coronary Z-score at 9-15 months was the Z-score at diagnosis. At our institution, longer illness and defervescence duration and the lack of IVIg administration were associated with not administering HDA. HDA duration did not affect the clinically relevant outcomes, particularly CAA persistence.

AB - BackgroundHigh-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD). Practice regarding HDA varies, and it is unclear whether HDA duration affects the long-term course.MethodsWe retrospectively studied KD patients at our hospital for over 10 years. Patients were categorized as having received HDA for 0, 1-7, or >7 days. Primary outcome was the maximum coronary Z-score at diagnosis and follow-up; secondary outcomes included inflammatory markers.ResultsOne hundred and three patients had HDA duration documented, of which 35 patients had coronary artery abnormalities (CAAs) at diagnosis. There was no difference in demographics or inflammatory markers between the HDA groups, and no difference in HDA duration between patients with or without CAAs. Seventeen patients received no HDA; they had longer illness and defervescence duration before diagnosis, and were less likely to receive IVIg. For CAAs, multivariate regression revealed that HDA duration did not predict the coronary Z-score at 9-15 months. Higher Z-score at diagnosis was associated with higher Z-score at 9-15 months.ConclusionThe only factor associated with coronary Z-score at 9-15 months was the Z-score at diagnosis. At our institution, longer illness and defervescence duration and the lack of IVIg administration were associated with not administering HDA. HDA duration did not affect the clinically relevant outcomes, particularly CAA persistence.

UR - http://www.scopus.com/inward/record.url?scp=85049105342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049105342&partnerID=8YFLogxK

U2 - 10.1038/pr.2018.44

DO - 10.1038/pr.2018.44

M3 - Article

C2 - 29554081

AN - SCOPUS:85049105342

VL - 83

SP - 1136

EP - 1145

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -